News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,340 Results
Type
Article (45458)
Company Profile (709)
Press Release (692162)
Multimedia
Podcasts (170)
Webinars (30)
Section
Business (211629)
Career Advice (2708)
Deals (37151)
Drug Delivery (149)
Drug Development (82631)
Employer Resources (179)
FDA (16642)
Job Trends (15880)
News (356513)
Policy (32724)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2190)
Academic (2)
Accelerated approval (44)
Adcomms (29)
Allergies (170)
Alliances (51992)
ALS (205)
Alzheimer's disease (1799)
Antibody-drug conjugate (ADC) (399)
Approvals (16922)
Artificial intelligence (658)
Autoimmune disease (240)
Automation (48)
Bankruptcy (385)
Best Places to Work (11769)
BIOSECURE Act (23)
Biosimilars (208)
Biotechnology (444)
Bladder cancer (174)
Brain cancer (67)
Breast cancer (690)
Cancer (5407)
Cardiovascular disease (481)
Career advice (2298)
Career pathing (46)
CAR-T (311)
CDC (45)
Celiac Disease (1)
Cell therapy (857)
Cervical cancer (42)
Clinical research (71104)
Collaboration (2027)
Company closure (7)
Compensation (1266)
Complete response letters (87)
COVID-19 (2732)
CRISPR (103)
C-suite (1031)
Cystic fibrosis (155)
Data (7073)
Decentralized trials (3)
Denatured (51)
Depression (165)
Dermatology (56)
Diabetes (567)
Diagnostics (7073)
Digital health (53)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (318)
Drug pricing (219)
Drug shortages (34)
Duchenne muscular dystrophy (276)
Earnings (92304)
Editorial (67)
Employer branding (24)
Employer resources (159)
Events (123479)
Executive appointments (1085)
FDA (20089)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (13)
Frontotemporal dementia (29)
Funding (1670)
Gene editing (229)
Generative AI (67)
Gene therapy (719)
GLP-1 (1168)
Government (4223)
Grass and pollen (8)
Guidances (395)
Healthcare (18485)
HIV (78)
Huntington's disease (56)
IgA nephropathy (95)
Immunology and inflammation (312)
Immuno-oncology (89)
Indications (156)
Infectious disease (3055)
Inflammatory bowel disease (215)
Inflation Reduction Act (15)
Influenza (132)
Intellectual property (279)
Interviews (523)
IPO (17462)
IRA (55)
Job creations (4490)
Job search strategy (1869)
JPM (68)
Kidney cancer (18)
Labor market (91)
Layoffs (654)
Leadership (42)
Legal (8234)
Liver cancer (99)
Longevity (27)
Lung cancer (725)
Lymphoma (403)
Machine learning (52)
Management (62)
Manufacturing (964)
MASH (191)
Medical device (14505)
Medtech (14588)
Mergers & acquisitions (20847)
Metabolic disorders (1538)
mRNA (198)
Multiple sclerosis (174)
NASH (21)
Neurodegenerative disease (422)
Neuropsychiatric disorders (108)
Neuroscience (3266)
Neurotech (1)
NextGen: Class of 2026 (6780)
Non-profit (3810)
Now hiring (74)
Obesity (758)
Opinion (343)
Ovarian cancer (183)
Pain (238)
Pancreatic cancer (262)
Parkinson's disease (349)
Partnered (36)
Patents (571)
Patient recruitment (605)
Peanut (65)
People (61847)
Pharmaceutical (128)
Pharmacy benefit managers (32)
Phase 1 (22176)
Phase 2 (31393)
Phase 3 (23579)
Pipeline (7128)
Policy (324)
Postmarket research (2432)
Preclinical (9273)
Press Release (66)
Prostate cancer (281)
Psychedelics (57)
Radiopharmaceuticals (322)
Rare diseases (1065)
Real estate (6222)
Recruiting (77)
Regulatory (25274)
Reports (49)
Research institute (2118)
Resumes & cover letters (420)
Rett syndrome (32)
RNA editing (21)
RSV (88)
Schizophrenia (172)
Series A (292)
Series B (211)
Service/supplier (27)
Sickle cell disease (112)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (43)
Startups (4018)
State (2)
Stomach cancer (21)
Supply chain (123)
Tariffs (98)
The Weekly (116)
Vaccines (1115)
Venture capital (109)
Weight loss (514)
Women's health (106)
Worklife (23)
Date
Today (93)
Last 7 days (652)
Last 30 days (2834)
Last 365 days (31467)
2026 (8129)
2025 (31679)
2024 (36728)
2023 (41460)
2022 (52107)
2021 (56089)
2020 (54104)
2019 (46689)
2018 (35529)
2017 (34218)
2016 (33344)
2015 (38983)
2014 (32405)
2013 (27736)
2012 (29038)
2011 (29045)
2010 (27057)
Location
Africa (877)
Alabama (97)
Alaska (6)
Arizona (287)
Arkansas (13)
Asia (44419)
Australia (7344)
California (12536)
Canada (3533)
China (1298)
Colorado (532)
Connecticut (545)
Delaware (374)
Europe (99274)
Florida (1851)
Georgia (399)
Hawaii (4)
Idaho (63)
Illinois (968)
India (86)
Indiana (586)
Iowa (24)
Japan (492)
Kansas (128)
Kentucky (46)
Louisiana (38)
Maine (80)
Maryland (1444)
Massachusetts (9149)
Michigan (378)
Minnesota (702)
Mississippi (7)
Missouri (144)
Montana (36)
Nebraska (27)
Nevada (138)
New Hampshire (87)
New Jersey (3378)
New Mexico (32)
New York (3267)
North Carolina (1679)
North Dakota (10)
Northern California (6164)
Ohio (368)
Oklahoma (25)
Oregon (50)
Pennsylvania (2495)
Puerto Rico (26)
Rhode Island (53)
South America (1259)
South Carolina (75)
South Dakota (1)
Southern California (4846)
Tennessee (192)
Texas (1950)
United States (44497)
Utah (363)
Vermont (1)
Virginia (314)
Washington D.C. (83)
Washington State (1032)
West Virginia (4)
Wisconsin (133)
Wyoming (2)
738,340 Results for "eli lilly and company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
April 1, 2026
·
3 min read
·
Heather McKenzie
Deals
Lilly Doubles Down on Insilico’s AI Medicines, Bets up to $2.75B
The Insilico Medicine agreement plays into Eli Lilly’s recent AI push, anchored by a partnership last year with NVIDIA to build a supercomputer to optimize drug discovery and shorten the development timeline.
March 30, 2026
·
2 min read
·
Tristan Manalac
China
Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
March 11, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
·
2 min read
·
Nick Paul Taylor
Diabetes
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data
Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.
March 19, 2026
·
2 min read
·
Tristan Manalac
GLP-1
Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts
Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists in treating substance use disorders.
March 30, 2026
·
6 min read
·
Catherine Offord
Press Releases
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
February 17, 2026
·
4 min read
Mergers & acquisitions
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking
Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma’s partnership with Nektar over atopic dermatitis therapy rezpeg.
October 20, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.
March 31, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
1 of 73,834
Next
